Final analysis of a trial of M72/AS01E vaccine to prevent Tuberculosis
The final analysis of a multi-site medical trial involving the University of Cape Town (UCT) has produced the first signal of a potentially effective vaccine against tuberculosis (TB) in almost 100 years.
Phase 3 efficacy study finds shortened 4-month TB drug therapy treatment equivalent to 6-months therapy
The New England Journal of Medicine has published the results of a clinical study which shows that in a randomised phase 3 clinical trial, a shortened 4-month TB treatment was equivalent to the standard 6-month TB treatment.
Read more
New multi-functional TB blood test validated
As part of a global research effort SATVI researchers have developed and validated a new, simple blood-based test to identify healthy people at risk of developing tuberculosis (TB) disease, and identify sub clinical or clinical TB.
Read more
World TB Day 2024: Yes! We can end TB
Join us in marking a pivotal moment in the battle against TB this World TB Day, March 24, 2024.
News from the South African Tuberculosis Vaccine Initiative.
SATVI scholar Dr Munyaradzi Musvosvi awarded prestigious scholarship from the Crick Africa Network
The Crick Africa Network has awarded SATVI's Dr Munyaradzi Musvosvi a prestigious fellowship through the African Career Acceleration Fellowship.
Read more
Major research publication: New classification of tuberculosis to support efforts to eliminate the disease
SATVI's Professor Tom Scriba has co-authored a major paper which provides new way to classify tuberculosis (TB) that aims to improve focus on the early stages of the disease appearing in the The Lancet Respiratory Medicine
Read more
World TB Day 2024: Yes! We can end TB
Join us in marking a pivotal moment in the battle against TB this World TB Day, March 24, 2024.
Read more
Latest News: SATVI awarded a Phase III RePORT grant to study novel TB diagnostics, drugs and vaccines.
The SAMRC has awarded SATVI a major grant in which it will lead the RePORT research consortium which will study basic science and biomarker research which will aid the search for novel TB diagnostics, drugs, and vaccines.
Read more
Vacancies
No vacancies found
Previous highlights
Video: World TB Day: Vaccine trial inspires SATVI clinicians to imagine a world without TB
On World TB Day, the University of Cape Town (UCT) shines the spotlight on phase three of a clinical trial led by clinicians at the South African Tuberculosis Vaccine Initiative (SATVI).
Download: SATVI 20 year history
The corporate history of the South African Tuberculosis Vaccine Initiative is available online. This history is the result of more than 20 interviews conducted over a period of about one year with SATVI staff and students, including ma
Download: SATVI 2022 Annual Report
The SATVI Annual Report 2022 is available for download.
SATVI researchers amongst the top UCT researchers studying BCG: 1989 - 2021
The University of Cape Town is leading international research into the only licensed TB vaccine, Bacille Calmette-Guerin (BCG), according to a new study.
Upcoming Events
8th SA TB Conference, 4 to 7 June 2024
The 8th SA TB conference will be taking place between 4 and 7 June 2024 in Durban at the Durban Convention Centre. The various sessions, posters, other proceedings will cover diverse aspects of TB and TB control.